CN108949640A - 短双歧杆菌ccfm1025、其发酵食品及其应用 - Google Patents
短双歧杆菌ccfm1025、其发酵食品及其应用 Download PDFInfo
- Publication number
- CN108949640A CN108949640A CN201810962590.4A CN201810962590A CN108949640A CN 108949640 A CN108949640 A CN 108949640A CN 201810962590 A CN201810962590 A CN 201810962590A CN 108949640 A CN108949640 A CN 108949640A
- Authority
- CN
- China
- Prior art keywords
- ccfm1025
- bifidobacterium breve
- bifidobacterium
- depressed
- mouse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186012 Bifidobacterium breve Species 0.000 title claims abstract description 43
- 235000021107 fermented food Nutrition 0.000 title claims abstract description 22
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 88
- 241000699666 Mus <mouse, genus> Species 0.000 claims abstract description 68
- 230000000994 depressogenic effect Effects 0.000 claims abstract description 57
- 230000000968 intestinal effect Effects 0.000 claims abstract description 30
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 27
- 210000002966 serum Anatomy 0.000 claims abstract description 26
- 241000699670 Mus sp. Species 0.000 claims abstract description 25
- 210000004556 brain Anatomy 0.000 claims abstract description 23
- 210000004027 cell Anatomy 0.000 claims abstract description 23
- 229940076279 serotonin Drugs 0.000 claims abstract description 21
- 241001430183 Veillonellaceae Species 0.000 claims abstract description 20
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims abstract description 14
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims abstract description 14
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims abstract description 13
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 12
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 12
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 241000204034 Mycoplasmataceae Species 0.000 claims abstract description 11
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 claims abstract description 11
- 101000830742 Homo sapiens Tryptophan 5-hydroxylase 1 Proteins 0.000 claims abstract description 10
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 10
- 102100024971 Tryptophan 5-hydroxylase 1 Human genes 0.000 claims abstract description 10
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 10
- 210000002322 enterochromaffin cell Anatomy 0.000 claims abstract description 8
- 239000002243 precursor Substances 0.000 claims abstract description 8
- 239000000126 substance Substances 0.000 claims abstract description 8
- 230000003248 secreting effect Effects 0.000 claims abstract description 7
- 238000004088 simulation Methods 0.000 claims abstract description 7
- 230000009467 reduction Effects 0.000 claims abstract description 6
- 230000006870 function Effects 0.000 claims description 19
- 235000013305 food Nutrition 0.000 claims description 13
- 241000731710 Allobaculum Species 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 230000000638 stimulation Effects 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- 239000006041 probiotic Substances 0.000 claims description 8
- 235000018291 probiotics Nutrition 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 235000013365 dairy product Nutrition 0.000 claims description 6
- 235000012055 fruits and vegetables Nutrition 0.000 claims description 6
- 210000000936 intestine Anatomy 0.000 claims description 6
- 210000003737 chromaffin cell Anatomy 0.000 claims description 5
- 230000005176 gastrointestinal motility Effects 0.000 claims description 5
- 238000004321 preservation Methods 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 4
- 208000037903 inflammatory enteropathy Diseases 0.000 claims description 4
- 240000007087 Apium graveolens Species 0.000 claims description 3
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 claims description 3
- 235000010591 Appio Nutrition 0.000 claims description 3
- 235000016068 Berberis vulgaris Nutrition 0.000 claims description 3
- 241000335053 Beta vulgaris Species 0.000 claims description 3
- 240000008067 Cucumis sativus Species 0.000 claims description 3
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 claims description 3
- 244000000626 Daucus carota Species 0.000 claims description 3
- 235000002767 Daucus carota Nutrition 0.000 claims description 3
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 3
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 235000013351 cheese Nutrition 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 235000015142 cultured sour cream Nutrition 0.000 claims description 3
- 208000037902 enteropathy Diseases 0.000 claims description 3
- 238000001727 in vivo Methods 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 208000028774 intestinal disease Diseases 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052804 chromium Inorganic materials 0.000 claims description 2
- 239000011651 chromium Substances 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims description 2
- SNIXRMIHFOIVBB-UHFFFAOYSA-N N-Hydroxyl-tryptamine Chemical compound C1=CC=C2C(CCNO)=CNC2=C1 SNIXRMIHFOIVBB-UHFFFAOYSA-N 0.000 claims 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 1
- 230000003579 anti-obesity Effects 0.000 claims 1
- 239000002054 inoculum Substances 0.000 claims 1
- 230000000508 neurotrophic effect Effects 0.000 claims 1
- 230000006872 improvement Effects 0.000 abstract description 6
- 241000894006 Bacteria Species 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 238000012360 testing method Methods 0.000 description 15
- 230000001580 bacterial effect Effects 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000010586 diagram Methods 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000006188 syrup Substances 0.000 description 7
- 235000020357 syrup Nutrition 0.000 description 7
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 210000001320 hippocampus Anatomy 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000012048 forced swim test Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000010172 mouse model Methods 0.000 description 5
- 210000002442 prefrontal cortex Anatomy 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 241000193830 Bacillus <bacterium> Species 0.000 description 4
- 206010014357 Electric shock Diseases 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000009191 jumping Effects 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 229940035613 prozac Drugs 0.000 description 4
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 4
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 4
- 230000035882 stress Effects 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 102000016938 Catalase Human genes 0.000 description 3
- 108010053835 Catalase Proteins 0.000 description 3
- 206010054089 Depressive symptom Diseases 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 3
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 3
- 102000003964 Histone deacetylase Human genes 0.000 description 3
- 108090000353 Histone deacetylase Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000009189 diving Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 230000008855 peristalsis Effects 0.000 description 3
- 230000001376 precipitating effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000009182 swimming Effects 0.000 description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 2
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000007415 Anhedonia Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 240000007124 Brassica oleracea Species 0.000 description 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 2
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 2
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- BGWGXPAPYGQALX-ARQDHWQXSA-N beta-D-fructofuranose 6-phosphate Chemical class OC[C@@]1(O)O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O BGWGXPAPYGQALX-ARQDHWQXSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000001917 fluorescence detection Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- 108091005482 5-HT4 receptors Proteins 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- GSXOAOHZAIYLCY-UHFFFAOYSA-N D-F6P Natural products OCC(=O)C(O)C(O)C(O)COP(O)(O)=O GSXOAOHZAIYLCY-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000010806 PrimeScriptTM RT Reagent kit Methods 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- -1 Tris saturated phenol Chemical class 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000003916 acid precipitation Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000002592 gangliocyte Anatomy 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000007433 nerve pathway Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003349 osteoarthritic effect Effects 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 108010004621 phosphoketolase Proteins 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- AGDSCTQQXMDDCV-UHFFFAOYSA-M sodium;2-iodoacetate Chemical compound [Na+].[O-]C(=O)CI AGDSCTQQXMDDCV-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C11/00—Milk substitutes, e.g. coffee whitener compositions
- A23C11/02—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins
- A23C11/10—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing or not lactose but no other milk components as source of fats, carbohydrates or proteins
- A23C11/103—Milk substitutes, e.g. coffee whitener compositions containing at least one non-milk component as source of fats or proteins containing or not lactose but no other milk components as source of fats, carbohydrates or proteins containing only proteins from pulses, oilseeds or nuts, e.g. nut milk
- A23C11/106—Addition of, or treatment with, microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C19/00—Cheese; Cheese preparations; Making thereof
- A23C19/02—Making cheese curd
- A23C19/032—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin
- A23C19/0323—Making cheese curd characterised by the use of specific microorganisms, or enzymes of microbial origin using only lactic acid bacteria, e.g. Pediococcus and Leuconostoc species; Bifidobacteria; Microbial starters in general
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C20/00—Cheese substitutes
- A23C20/02—Cheese substitutes containing neither milk components, nor caseinate, nor lactose, as sources of fats, proteins or carbohydrates
- A23C20/025—Cheese substitutes containing neither milk components, nor caseinate, nor lactose, as sources of fats, proteins or carbohydrates mainly containing proteins from pulses or oilseeds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Rheumatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810962590.4A CN108949640B (zh) | 2018-08-22 | 2018-08-22 | 短双歧杆菌ccfm1025、其发酵食品及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810962590.4A CN108949640B (zh) | 2018-08-22 | 2018-08-22 | 短双歧杆菌ccfm1025、其发酵食品及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108949640A true CN108949640A (zh) | 2018-12-07 |
CN108949640B CN108949640B (zh) | 2020-08-04 |
Family
ID=64473681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810962590.4A Active CN108949640B (zh) | 2018-08-22 | 2018-08-22 | 短双歧杆菌ccfm1025、其发酵食品及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108949640B (zh) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110093286A (zh) * | 2019-03-19 | 2019-08-06 | 江南大学 | 假小链双歧杆菌ccfm1046、其组合物、发酵食品、用途、菌剂及其菌剂制备方法 |
CN110664848A (zh) * | 2019-11-19 | 2020-01-10 | 江南大学 | CCFM1025在制备缓解自闭症和吸附PCBs的食品或药物中的应用 |
CN111109359A (zh) * | 2019-12-29 | 2020-05-08 | 江南大学 | 多功能乳酸片球菌ccfm1105、其发酵食品及应用 |
WO2020133805A1 (zh) * | 2018-12-26 | 2020-07-02 | 江南大学 | 一种具有抗流感能力的益生菌混合制剂及其应用 |
CN111743159A (zh) * | 2020-07-17 | 2020-10-09 | 江南大学 | 复合微生物制剂及缓解抑郁和便秘的应用 |
CN112940980A (zh) * | 2021-03-24 | 2021-06-11 | 江南大学 | 缓解便秘的两歧双歧杆菌及其制备的发酵食品与益生菌制剂 |
CN112972502A (zh) * | 2021-04-30 | 2021-06-18 | 江南大学 | 短双歧杆菌ccfm1025在缓解阿尔兹海默症中的应用 |
CN113170820A (zh) * | 2021-05-20 | 2021-07-27 | 浙江李子园食品股份有限公司 | 一种含共轭亚油酸和共轭亚麻酸的发酵乳及其制备方法 |
CN113207960A (zh) * | 2020-08-31 | 2021-08-06 | 内蒙古蒙牛乳业(集团)股份有限公司 | 改善肥胖的乳双歧杆菌MN-Gup发酵乳及制备方法 |
CN113209139A (zh) * | 2020-08-31 | 2021-08-06 | 内蒙古蒙牛乳业(集团)股份有限公司 | 乳双歧杆菌MN-Gup改善肥胖及其特征肠道菌群用途 |
CN114533765A (zh) * | 2022-03-17 | 2022-05-27 | 江南大学 | 短双歧杆菌ccfm1025在调节幼年神经发育中的应用 |
CN114717148A (zh) * | 2022-03-17 | 2022-07-08 | 江南大学 | 缓解抑郁情绪的副干酪乳杆菌ccfm1229及其应用 |
CN115590889A (zh) * | 2022-10-11 | 2023-01-13 | 江南大学(Cn) | 一种调节生物昼夜节律的短双歧杆菌及其应用 |
CN115919904A (zh) * | 2022-11-10 | 2023-04-07 | 江南大学 | 一株可保护肠道上皮细胞层的短双歧杆菌及应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009043856A3 (en) * | 2007-10-01 | 2009-07-16 | Univ College Cork Nat Univ Ie | Modulation of tissue fatty acid composition of a host by human gut bacteria |
CN102202527A (zh) * | 2008-11-03 | 2011-09-28 | 雀巢产品技术援助有限公司 | 包含益生菌并改善睡眠模式的营养组合物 |
EP2818056A1 (en) * | 2013-06-25 | 2014-12-31 | Biosearch S.A. | Probiotic bacteria comprising metals, metal nanoparticles and uses thereof |
WO2017209156A1 (ja) * | 2016-05-31 | 2017-12-07 | 森永乳業株式会社 | 脳機能改善剤 |
CN108430482A (zh) * | 2015-11-10 | 2018-08-21 | 伊丽莎白·麦克纳 | 细胞氧化还原水平的控制 |
-
2018
- 2018-08-22 CN CN201810962590.4A patent/CN108949640B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009043856A3 (en) * | 2007-10-01 | 2009-07-16 | Univ College Cork Nat Univ Ie | Modulation of tissue fatty acid composition of a host by human gut bacteria |
CN102202527A (zh) * | 2008-11-03 | 2011-09-28 | 雀巢产品技术援助有限公司 | 包含益生菌并改善睡眠模式的营养组合物 |
EP2818056A1 (en) * | 2013-06-25 | 2014-12-31 | Biosearch S.A. | Probiotic bacteria comprising metals, metal nanoparticles and uses thereof |
CN108430482A (zh) * | 2015-11-10 | 2018-08-21 | 伊丽莎白·麦克纳 | 细胞氧化还原水平的控制 |
WO2017209156A1 (ja) * | 2016-05-31 | 2017-12-07 | 森永乳業株式会社 | 脳機能改善剤 |
Non-Patent Citations (2)
Title |
---|
岳滢滢等: "从抑郁致功能性消化不良进行肝胃不和证研究的思路分析", 《辽宁中医杂志》 * |
顾瑞霞等: "一株短双歧杆菌GRX031益生特性的研究", 《中国乳品工业》 * |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11369648B2 (en) | 2018-12-26 | 2022-06-28 | Jiangnan University | Probiotic mixed preparation with anti-influenza ability and application thereof |
WO2020133805A1 (zh) * | 2018-12-26 | 2020-07-02 | 江南大学 | 一种具有抗流感能力的益生菌混合制剂及其应用 |
CN110093286A (zh) * | 2019-03-19 | 2019-08-06 | 江南大学 | 假小链双歧杆菌ccfm1046、其组合物、发酵食品、用途、菌剂及其菌剂制备方法 |
CN110664848A (zh) * | 2019-11-19 | 2020-01-10 | 江南大学 | CCFM1025在制备缓解自闭症和吸附PCBs的食品或药物中的应用 |
CN111109359A (zh) * | 2019-12-29 | 2020-05-08 | 江南大学 | 多功能乳酸片球菌ccfm1105、其发酵食品及应用 |
CN111109359B (zh) * | 2019-12-29 | 2022-09-02 | 江南大学 | 多功能乳酸片球菌ccfm1105、其发酵食品及应用 |
CN111743159A (zh) * | 2020-07-17 | 2020-10-09 | 江南大学 | 复合微生物制剂及缓解抑郁和便秘的应用 |
CN113207960B (zh) * | 2020-08-31 | 2023-02-28 | 内蒙古蒙牛乳业(集团)股份有限公司 | 改善肥胖的乳双歧杆菌MN-Gup发酵乳及制备方法 |
CN113209139B (zh) * | 2020-08-31 | 2022-09-23 | 内蒙古蒙牛乳业(集团)股份有限公司 | 乳双歧杆菌MN-Gup改善肥胖及其特征肠道菌群用途 |
CN113207960A (zh) * | 2020-08-31 | 2021-08-06 | 内蒙古蒙牛乳业(集团)股份有限公司 | 改善肥胖的乳双歧杆菌MN-Gup发酵乳及制备方法 |
CN113209139A (zh) * | 2020-08-31 | 2021-08-06 | 内蒙古蒙牛乳业(集团)股份有限公司 | 乳双歧杆菌MN-Gup改善肥胖及其特征肠道菌群用途 |
CN112940980A (zh) * | 2021-03-24 | 2021-06-11 | 江南大学 | 缓解便秘的两歧双歧杆菌及其制备的发酵食品与益生菌制剂 |
CN112940980B (zh) * | 2021-03-24 | 2022-07-22 | 江南大学 | 缓解便秘的两歧双歧杆菌及其制备的发酵食品与益生菌制剂 |
CN112972502B (zh) * | 2021-04-30 | 2022-09-27 | 江南大学 | 短双歧杆菌ccfm1025在缓解阿尔兹海默症中的应用 |
CN112972502A (zh) * | 2021-04-30 | 2021-06-18 | 江南大学 | 短双歧杆菌ccfm1025在缓解阿尔兹海默症中的应用 |
CN113170820B (zh) * | 2021-05-20 | 2022-06-17 | 浙江李子园食品股份有限公司 | 一种含共轭亚油酸和共轭亚麻酸的发酵乳及其制备方法 |
CN113170820A (zh) * | 2021-05-20 | 2021-07-27 | 浙江李子园食品股份有限公司 | 一种含共轭亚油酸和共轭亚麻酸的发酵乳及其制备方法 |
CN114717148A (zh) * | 2022-03-17 | 2022-07-08 | 江南大学 | 缓解抑郁情绪的副干酪乳杆菌ccfm1229及其应用 |
CN114533765A (zh) * | 2022-03-17 | 2022-05-27 | 江南大学 | 短双歧杆菌ccfm1025在调节幼年神经发育中的应用 |
CN114717148B (zh) * | 2022-03-17 | 2023-08-25 | 江南大学 | 缓解抑郁情绪的副干酪乳杆菌ccfm1229及其应用 |
CN114533765B (zh) * | 2022-03-17 | 2023-08-25 | 江南大学 | 短双歧杆菌ccfm1025在调节幼年神经发育中的应用 |
CN115590889A (zh) * | 2022-10-11 | 2023-01-13 | 江南大学(Cn) | 一种调节生物昼夜节律的短双歧杆菌及其应用 |
CN115919904A (zh) * | 2022-11-10 | 2023-04-07 | 江南大学 | 一株可保护肠道上皮细胞层的短双歧杆菌及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN108949640B (zh) | 2020-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108949640A (zh) | 短双歧杆菌ccfm1025、其发酵食品及其应用 | |
CN109055269A (zh) | 长双歧杆菌婴儿亚种ccfm687、其发酵食品及其应用 | |
US20220072067A1 (en) | Pediococcus acidilactici CCFM6432 for Alleviating Depression, Food Fermented Thereby and Application Thereof | |
CN108913615A (zh) | 用作用于营养和医药应用的益生菌剂的细菌 | |
CN113215034B (zh) | 一株能够缓解阿尔兹海默症并增加粪便乙酸含量的短双歧杆菌及其应用 | |
CN112972502B (zh) | 短双歧杆菌ccfm1025在缓解阿尔兹海默症中的应用 | |
JP2020026437A (ja) | 長寿促進のための、パラカゼイ gks6の活性物質、それを含む組成物、およびその使用 | |
CN107075455A (zh) | 具有抗炎症及代谢疾病改善功效的植物乳杆菌hac01菌株及其用途 | |
CN1931879A (zh) | 银耳杂多糖或其提取物的新用途 | |
CN111743159B (zh) | 复合微生物制剂及缓解抑郁和便秘的应用 | |
CN116656534B (zh) | 一种改善运动能力的长双歧杆菌长亚种及其应用 | |
WO2021143621A1 (zh) | Anaerostipes sp B2131菌及其在炎症性肠病中的应用 | |
CN101328468A (zh) | 抗过敏的乳酸菌 | |
CN113215035A (zh) | 长双歧杆菌和动物双歧杆菌的制备及其在抗衰老方面的应用 | |
CN104997813B (zh) | 益生微生态制剂的制备方法 | |
JP2020075902A (ja) | ビフィドバクテリウムラクティスgkk2の活性物質、それを含む組成物及びそれによって長寿命化を促進する方法 | |
CN106389475B (zh) | 脆弱拟杆菌在预防和/或治疗脑膜炎中的应用 | |
RU2546253C2 (ru) | Способ получения персонифицированного аутопробиотического продукта и способ лечения синдрома раздраженной кишки с использованием этого продукта | |
CN114410531B (zh) | 降低血浆tmao及缓解、预防动脉粥样硬化的长双歧杆菌ccfm1216及其应用 | |
CN114410532B (zh) | 一株降低血浆氧化三甲胺和盲肠三甲胺水平的长双歧杆菌及其应用 | |
CN113943683B (zh) | 一株缓解便秘并增加粪便总胆汁酸含量的长双歧杆菌长亚种及其应用 | |
CN110141584A (zh) | 一种开菲尔乳杆菌m11在抑菌及作为治疗ⅱ型糖尿病药剂的活性成分的应用 | |
CN110144307A (zh) | 一种抗肠出血性大肠杆菌的格氏乳杆菌及制备的禽用复合益生菌制剂及应用 | |
CN102702373B (zh) | 一种乳酸杆菌细胞壁完整肽聚糖及其在提高iec抗菌肽表达水平中的应用 | |
CN113025530B (zh) | 一株缓解泻剂结肠的两歧双歧杆菌及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210728 Address after: 214000 room 602, No.5, beichansi lane, Chong'an District, Wuxi City, Jiangsu Province Patentee after: Zhao Jianxin Address before: Jiangnan University, no.1800 Lihu Avenue, Binhu District, Wuxi City, Jiangsu Province Patentee before: Jiangnan University |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210914 Address after: Room 102-48, Jiangda Science Park, No. 99, Jinxi Road, Binhu District, Wuxi City, Jiangsu Province, 214000 Patentee after: Wuxi Shisheng Zhenxuan Biotechnology Co.,Ltd. Address before: 214000 room 602, No.5, beichansi lane, Chong'an District, Wuxi City, Jiangsu Province Patentee before: Zhao Jianxin |
|
TR01 | Transfer of patent right |